La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Adlai Nortye a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Adlai Nortye..

Adlai Nortye (NASDAQ:ANL) Azioni, Catena delle Opzioni

Adlai Nortye

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye Ltd

Aton Resources Inc

ANFIELD ENERGY INC by Anfield Energy Inc.

Anfield Energy Inc

TD Cowen analyst Vivien Azer downgrades Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) from Buy to Hold and lowers the price target from $50 to $48.

News

Downgrades

Price Target

Analyst Ratings

BF/B

TD Cowen Downgrades Brown-Forman to Hold, Lowers Price Target to $48

WIIM

CHTR

Charter Communications shares are trading higher after Benchmark maintained a Buy rating on the stock and raised its price target from $440 to $450.

Management

CLBT

Cellebrite CEO Yossi Carmil To Step Down After Nearly 20 Years; Executive Chairman Thomas E. Hogan To Serve As Interim CEO Pending New Appointment

Piper Sandler analyst Christopher Raymond maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Overweight and raises the price target from $4 to $5.

KPTI

Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Raises Price Target to $5

American Electric Power Company, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) reported the&nbsp;third quarter revenue of&nbsp;$5.42 billion,&nbsp;missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769709/aep-reports-third-quarter-2024-earnings-introduces-new-growth-rate-and-capital-plan" rel="noreferrer noopener">consensus of&nbsp;$5.434 billion</a>.
Commercial load increased more than&nbsp;10%&nbsp;year-over-year through the&nbsp;third quarter. The company projects commercial load to grow an average of 20% annually over the next three years on the basis of customer contracts signed so far.
Total energy distribution fell 1.0% in the Vertically Integrated Utilities segment and&nbsp;rose 4.1% in the Transmission &amp; Distribution Utilities segment.&nbsp;
Adjusted operating earnings rose to&nbsp;$985.4 million from&nbsp;$923.8 million a year ago.&nbsp;
Adjusted operating earnings from Vertically Integrated Utilities rose to&nbsp;$572.4 million from&nbsp;$520.0 million the prior year, and AEP Transmission Holdco grew to&nbsp;$214.7 million from&nbsp;$202.9 million&nbsp;in the prior&nbsp;year&#8217;s quarter.
Adjusted EPS&nbsp;of&nbsp;$1.85 <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beat the consensus of&nbsp;$1.80</a>.
FY24&nbsp;Outlook: American Electric Power narrowed adjusted operating earnings per share&nbsp;guidance&nbsp;from&nbsp;$5.53 &#8211; $5.73&nbsp;to $5.58 &#8211; $5.68<a target="_blank" href="https://www.benzinga.com//node/40038448" rel="noreferrer noopener"> vs.&nbsp;consensus of&nbsp;$5.62</a>.
The company sees FY25 adjusted EPS of $5.75 &#8211; $5.95 <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">vs consensus of $5.98</a>. The company now expects a long-term growth rate outlook of 6% to 8% (vs. 6% to 7% prior).
Bill Fehrman, AEP president and chief executive officer, said, &#8220;AEP has a strong foundation and significant growth opportunities ahead, and we are confident in our ability to execute our strategy and deliver on our promises. This confidence is reflected in our new&nbsp;6%-8%&nbsp;long-term growth rate and expanded capital investment plan of&nbsp;$54 billion&nbsp;over the next five years, along with our commitment to a strong balance sheet.&#8221;
Investors can gain exposure to the stock via&nbsp;Listed Funds Trust TrueShares Eagle Global Renewable Energy Income ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNWZ#NYSE">RNWZ</a>)&nbsp;SPDR Select Sector Fund – Utilities&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>).
Price Action: AEP shares are down 0.90% at $99.50 premarket at the last check Wednesday.
Photo by american-public-power-association- for Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41254312/hurricane-milton-descends-on-florida-analysts-warn-of-impact-on-disney-nexteras-flo" target="_blank" rel="noreferrer noopener">Hurricane Milton Descends On Florida: Analysts Warn Of Impact On Disney, NextEra&#8217;s Florida Power &amp; Light, Regional Banks</a></li>
</ul>

Earnings

Equities

Large Cap

Guidance

RNWZ

American Electric Power Q3: EPS Beat, Revenue Miss, 10% Commercial Load Jump & More

Ontrak, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>), a leading AI-powered and telehealth-enabled behavioral healthcare company, today announced a continuing expansion of its strategic partnership with Sentara Health Plans in the Commonwealth of Virginia.

OTRK

Ontrak Health Expands Behavioral Health Solutions With Sentara Health Plans In The Commonwealth Of Virginia For Commercial And Marketplace Populations

Piper Sandler analyst John Barnidge maintains Horace Mann Educators (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMN#NYSE">HMN</a>) with a Neutral and raises the price target from $36 to $42.

Piper Sandler Maintains Neutral on Horace Mann Educators, Raises Price Target to $42

Bit Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) ("Bit Digital" or the "Company"),&nbsp;a global platform for high-performance computing ("HPC") infrastructure and digital asset production headquartered in New York, announced its unaudited digital asset production, HPC services revenue, and corporate updates for the month of October 2024.
Corporate Highlights for October 2024
<ul>
<li>The Company had 256 servers actively generating revenue from its initial Bit Digital AI contract, as of October 31, 2024. The Company earned approximately $4.3 million of unaudited revenue from this contract during the month of October 2024.</li>
<li>In October 2024, the Company produced 52.2&nbsp;BTC, a 1.4% increase compared to the prior month.</li>
<li>The Company's active hash rate was approximately 2.43 EH/s as of October 31, 2024.</li>
<li>Treasury holdings of&nbsp;BTC and ETH were 781.2 and 27,503.4 with a fair market value of approximately $54.8 million and $69.2 million, respectively, on October 31, 2024.</li>
<li>The&nbsp;BTC equivalent[1] of our digital asset holdings as of October 31, 2024, was approximately 1,768.6 or approximately $124.2 million.</li>
<li>The Company had cash and cash equivalents of $79.8 million and total liquidity (defined as cash and cash equivalents,&nbsp;USDC, and the fair market value of digital assets) of approximately $203.9 million, as of October 31, 2024.</li>
</ul>

BTBT

Bit Digital, Inc. Announces Monthly Production Update For October 2024; Produced 52.2 BTC, A 1.4% Increase MoM

Emerson Electric shares are trading higher after Deutsche Bank and Baird raised their respective price targets on the stock.

Rosenblatt analyst Mike Genovese maintains Infinera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INFN#NASDAQ">INFN</a>) with a Neutral and maintains $6.65 price target.

INFN

Rosenblatt Maintains Neutral on Infinera, Maintains $6.65 Price Target

Piper Sandler analyst Jason Bednar maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Overweight and raises the price target from $165 to $180.

MASI

Piper Sandler Maintains Overweight on Masimo, Raises Price Target to $180

Piper Sandler analyst Harsh Kumar maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Overweight and lowers the price target from $100 to $85.

MCHP

Piper Sandler Maintains Overweight on Microchip Technology, Lowers Price Target to $85

United States Antimony Corporation ("USAC", or the "Company"), (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAMY#NYSE">UAMY</a>), a leader in the processing of critical minerals, has announced today that it has successfully staked and recorded an additional 24 new claims totaling 3,840 acres (6 square miles) on Alaska State lands near Stibnite Creek, located in the Tok area of Alaska. This strategic move places UAMY in a known antimony-rich region along the Alaska Highway, approximately 200 miles southeast of Fairbanks. With this addition, the Company now controls a total of 93 claims totaling 14,880 acres in Alaska, most of which is either associated with antimony or other critical minerals.

UAMY

United States Antimony Corporation Further Expands Alaska Mining Land Ownership Position With Acquisition Of Stibnite Creek Antimony Claims; No Financial Terms Disclosed

Piper Sandler analyst Biren Amin maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Neutral and lowers the price target from $40 to $32.

APLS

Piper Sandler Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $32

TD Cowen analyst Robert Moskow upgrades Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from Sell to Hold and raises the price target from $155 to $170.

Upgrades

TD Cowen Upgrades Clorox to Hold, Raises Price Target to $170

Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.44) by 52.27 percent. This is a 43.24 percent increase over losses of $(0.37) per share from the same period last year. The company reported $14.97 million in sales this quarter.

Earnings Beats

BRNS

Barinthus Biotherapeutics Q3 EPS $(0.21) Beats $(0.44) Estimate, Sales $14.97M

Rosenblatt analyst Hans Mosesmann maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and maintains $90 price target.

Rosenblatt Maintains Buy on Microchip Technology, Maintains $90 Price Target

Dividends

ADP Increases Quarterly Dividend From $1.40 To $1.54 Per Share

Greystone Housing Impact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHI#NYSE">GHI</a>) reported quarterly losses of $(0.23) per share. The company reported quarterly sales of $24.346 million which missed the analyst consensus estimate of $25.908 million by 6.03 percent. This is a 8.04 percent decrease over sales of $26.474 million the same period last year.

Earnings Misses

Greystone Housing Impact Q3 2024 GAAP EPS $(0.23), Sales $24.346M Miss $25.908M Estimate

TD Cowen analyst Robert Moskow downgrades MGP Ingredients (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGPI#NASDAQ">MGPI</a>) from Buy to Hold and lowers the price target from $66 to $50.

MGPI

TD Cowen Downgrades MGP Ingredients to Hold, Lowers Price Target to $50

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off the trading week with a look at the biggest pre-market stock movers for Monday morning!



Moving stocks this morning are earnings, investments, a delisting and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Moolec Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlec-stock-quote/">MLEC</a>) stock is rocketing more than 67% on approval for its <a href="https://www.nasdaq.com/press-release/moolec-becomes-first-molecular-farming-company-to-achieve-usda-approval-for-plant">plant-groan animal proteins</a>.</li>



<li>OLB Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/olb-stock-quote/">OLB</a>) shares are soaring over 46% with heavy pre-market trading.</li>



<li>Complete Solaria (NASDAQ:<a href="https://investorplace.com/stock-quotes/cslr-stock-quote/">CSLR</a>) stock is surging more than 42% <a href="https://www.nasdaq.com/press-release/retail-stock-sector-and-chairman-t.j.-rodgers-invest-in-complete-solaria-2024-04-21">on investment news</a>.</li>



<li>SuperCom (NASDAQ:<a href="https://investorplace.com/stock-quotes/spcb-stock-quote/">SPCB</a>) shares are gaining over 33% ahead of its <a href="https://www.nasdaq.com/press-release/supercom-to-report-fourth-quarter-and-full-year-2023-financial-results-on-april-22">Q4 2023 earnings report</a> this morning.</li>



<li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rising more than 18% on Monday morning.</li>



<li>Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) shares are increasing over 17% without any clear news this morning.</li>



<li>Palisade Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/pali-stock-quote/">PALI</a>) stock is climbing more than 16% despite a lack of news today.</li>



<li>Global Gas (NASDAQ:<a href="https://investorplace.com/stock-quotes/hgas-stock-quote/">HGAS</a>) shares are heading over 14% higher on Monday.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) stock is jumping more than 13% on Monday morning.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) shares are up over 13% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Vaxxinity (NASDAQ:<a href="https://investorplace.com/stock-quotes/vaxx-stock-quote/">VAXX</a>) stock is crashing more than 55% on the company&rsquo;s <a href="https://finance.yahoo.com/news/vaxxinity-announces-intention-voluntarily-delist-202700884.html">plans to delist its shares</a>.</li>



<li>EzFill (NASDAQ:<a href="https://investorplace.com/stock-quotes/ezfl-stock-quote/">EZFL</a>) shares are plummeting close to 37% this morning.</li>



<li>Hepion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) stock is diving over 29% on plans to <a href="https://www.nasdaq.com/press-release/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-2b-ascend-nash-trial">wind down a clinical trial</a>.</li>



<li>iLearningEngines (NASDAQ:<a href="https://investorplace.com/stock-quotes/aile-stock-quote/">AILE</a>) shares are tumbling more than 21% after <a href="https://finance.yahoo.com/news/ilearningengines-inc-becomes-publicly-traded-200500132.html">going public last week</a>.</li>



<li>Redwoods Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/rwod-stock-quote/">RWOD</a>) stock is taking an over 15% beating <a href="https://investorplace.com/2024/04/why-is-redwoods-acquisition-rwod-stock-up-72-today/">after a recent rally</a>.</li>



<li>Biophytis (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpts-stock-quote/">BPTS</a>) shares are sliding more than 15% ahead of <a href="https://www.nasdaq.com/press-release/biophytis-announces-ratio-change-under-its-american-depositary-receipt-adr-program-0">a ratio change tomorrow</a>.</li>



<li>Adlai Nortye (NASDAQ:<a href="https://investorplace.com/stock-quotes/anl-stock-quote/">ANL</a>) stock is dropping nearly 15% today.</li>



<li>BioSig Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsgm-stock-quote/">BSGM</a>) shares are falling over 13% this morning.</li>



<li>Sunshine Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbfm-stock-quote/">SBFM</a>) stock is decreasing more than 12% today.</li>



<li>Indonesia Energy (NYSEMKT:<a href="https://investorplace.com/stock-quotes/indo-stock-quote/">INDO</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-april-22nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Adlai Nortye Ltd. Sponsored ADR (ANL) has released an update. Adlai Nortye Ltd., a biotech firm, will present preliminary data at ASCO 2024 on its ...

Adlai Nortye to Unveil Cancer Drug Data at ASCO 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning!



Moving stocks this morning are new agreements and deals, clinical trial data, a bankruptcy filing and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) stock is rocketing more than 205% after announcing a <a href="https://www.nasdaq.com/press-release/microalgo-inc-nasdaq-mlgo-announced-jointly-establish-micro-consciousness-quantum">joint micro-consciousness quantum research center</a> with WIMI (NASDAQ:<a href="https://investorplace.com/stock-quotes/wimi-stock-quote/">WIMI</a>).</li>



<li>Fresh2 Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/fres-stock-quote/">FRES</a>) shares are soaring over 74% alongside heavy pre-market trading.</li>



<li>Core Scientific (NASDAQ:<a href="https://investorplace.com/stock-quotes/corz-stock-quote/">CORZ</a>) stock is surging more than 48% on an <a href="https://www.businesswire.com/news/home/20240603752657/en/Core-Scientific-to-Provide-Approximately-200-MW-of-Infrastructure-to-Host-CoreWeave%E2%80%99s-High-Performance-Computing-Services-Capturing-Significant-AI-Compute-Opportunity">artificial intelligence (AI) infrastructure deal</a>.</li>



<li>Annexon (NASDAQ:<a href="https://investorplace.com/stock-quotes/annx-stock-quote/">ANNX</a>) shares are increasing over 33% on positive <a href="https://www.nasdaq.com/press-release/annexon-announces-positive-topline-results-pivotal-phase-3-trial-first-class-c1q">Phase 3 clinical trial results</a>.</li>



<li>Plutonian Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/pltn-stock-quote/">PLTN</a>) stock is rising close to 30% without any clear news this morning.</li>



<li>Datasea (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtss-stock-quote/">DTSS</a>) shares are gaining more than 21% on Tuesday morning.</li>



<li>SunLink Health Systems (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ssy-stock-quote/">SSY</a>) stock is climbing over 21% after <a href="https://www.nasdaq.com/press-release/sunlink-health-systems-inc-announces-sale-trace-extended-care-rehab-2024-06-03">selling some of its assets</a>.</li>



<li>Lexaria Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/lexx-stock-quote/">LEXX</a>) shares are heading 18% higher on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318368667&amp;type=PDF&amp;symbol=LEXX&amp;cdn=3c5f428b59a4d15cb4a8011d5c00dc9b&amp;companyName=Lexaria+Bioscience+Corp.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-06-03">secondary stock offering</a>.</li>



<li>FibroGen (NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) stock is jumping more than 16% on a <a href="https://finance.yahoo.com/news/fibrogen-announces-clinical-trial-supply-200500592.html">new clinical trial agreement</a>.</li>



<li>Adlai Nortye (NASDAQ:<a href="https://investorplace.com/stock-quotes/anl-stock-quote/">ANL</a>) shares are up nearly 16% on Tuesday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Lufax (NYSE:<a href="https://investorplace.com/stock-quotes/lu-stock-quote/">LU</a>) stock is plummeting more than 51% without any apparent news from the company.</li>



<li>Hywin (NASDAQ:<a href="https://investorplace.com/stock-quotes/hyw-stock-quote/">HYW</a>) shares are diving over 24% after a massive rally on Monday.</li>



<li>Avalon Globocare (NASDAQ:<a href="https://investorplace.com/stock-quotes/albt-stock-quote/">ALBT</a>) stock is tumbling more than 20% after a major rally yesterday.</li>



<li>Binah Capital (NASDAQ:<a href="https://investorplace.com/stock-quotes/bcg-stock-quote/">BCG</a>) shares are taking an over 17% beating without any news to report today.</li>



<li>CalAmp (NASDAQ:<a href="https://investorplace.com/stock-quotes/camp-stock-quote/">CAMP</a>) stock is sliding more than 15% following <a href="https://finance.yahoo.com/news/calamp-reaches-comprehensive-agreement-significantly-132500316.html">a bankruptcy filing</a>.</li>



<li>Sequans Communications (NYSE:<a href="https://investorplace.com/stock-quotes/sqns-stock-quote/">SQNS</a>) shares are dropping over 14% on Tuesday morning.</li>



<li>Direxion Daily MSCI India Bull 2X Shares (NYSEARCA:<a href="https://investorplace.com/stock-quotes/indl-stock-quote/">INDL</a>) are falling more than 14% this morning.</li>



<li>MingZhu Logistics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ygmz-stock-quote/">YGMZ</a>) stock is slipping over 14% after a rally yesterday.</li>



<li>Primech (NASDAQ:<a href="https://investorplace.com/stock-quotes/pmec-stock-quote/">PMEC</a>) shares are dipping 14% after jumping yesterday.</li>



<li>A2Z Smart Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/az-stock-quote/">AZ</a>) stock closes out our pre-market stock movers down over 12%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-june-4th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Adlai Nortye Ltd. Sponsored ADR (ANL) has released an update. Adlai Nortye Ltd. announced a significant leadership change with Dr. Lars E. Birgerso...

Adlai Nortye Announces Executive Leadership Transition

Adlai Nortye Ltd. Sponsored ADR (ANL) has released an update. Adlai Nortye Ltd. has reported its first-half financial results for 2024, including a...

Adlai Nortye Reports Strong 2024 Mid-Year Results

Adlai Nortye reports 1H results

Adlai Nortye Ltd. Sponsored ADR (ANL) has received a new Buy rating, initiated by H.C. Wainwright analyst, Joseph Pantginis. Joseph Pantginis has g...

Buy Rating Affirmed for Adlai Nortye Amid Strong Pipeline and Strategic Immuno-Oncology Focus

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Adlai Nortye Ltd. Sponsored ADR (ANL – Research Report). The associ...

Adlai Nortye Ltd.'s Promising Oncology Pipeline: Key Updates on AN4005 and AN2025 Drive Buy Rating

Warning: ANL is at high risk of performing badly

AILE

ALBT

ANNX

BPTS

BSGM

CAMP

CORZ

CSLR

DRMA

DTSS

EZFL

FGEN

FRES

GRTX

HEPA

HGAS

INDL

INDO

LEXX

MLEC

MLGO

PALI

PLTN

PMEC

PRTG

RWOD

SBFM

SOAR

SPCB

SQNS

VAXX

WIMI

YGMZ

Health Care

Press Releases

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

Comments

Adlai Nortye

Adlai Nortye (ANL) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO